NAMI-A
CAS: 201653-76-1
Ref. 3D-BIA65376
1mg | To inquire | ||
5mg | To inquire | ||
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire |
Product Information
- Ruthenate(1-), tetrachloro(1H-imidazole-κN3)[(sulfinyl-κS)bis[methane]]-, (OC-6-11)-, hydrogen, compd. with 1H-imidazole (1:1)
- Ruthenate(1-), tetrachloro(1H-imidazole-κN3)[1,1′-(sulfinyl-κS)bis[methane]]-, (OC-6-11)-, hydrogen, compd. with 1H-imidazole (1:1:1)
- 1H-Imidazole (OC-6-11)-tetrachloro(1H-imidazole-κN3)[1,1′-(sulfinyl-κS)bis[methane]]ruthenate(1-) (1:1)
- 1H-Imidazole, mono[(OC-6-11)-tetrachloro(1H-imidazole-κN3)[(sulfinyl-κS)bis[methane]]ruthenate(1-)]
Nami-A is an experimental drug that has been shown to have significant cytotoxicity against carcinoma cell lines and solid tumours. Nami-A is a small molecule that binds to integrin receptors on the surface of cells, inhibiting the production of matrix metalloproteinase-9 (MMP-9). In vivo studies with Nami-A in mice showed that mitochondrial membrane potential was reduced and there was a decrease in redox potentials. The MMP-9 inhibition by Nami-A may be due to its ability to inhibit oxidative stress.
Chemical properties
Technical inquiry about: 3D-BIA65376 NAMI-A
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.